WallStSmart

PepsiCo Inc (PEP)vsPrenetics Global Ltd (PRE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

PepsiCo Inc generates 80607% more annual revenue ($96.90B vs $120.07M). PEP leads profitability with a 10.8% profit margin vs -42.0%. PEP earns a higher WallStSmart Score of 71/100 (B).

PEP

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 8.0Value: 6.0Quality: 4.0
Piotroski: 3/9Altman Z: 2.26

PRE

Avoid

32

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -0.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PEPFair Value (-1.9%)

Margin of Safety

-1.9%

Fair Value

$140.22

Current Price

$139.56

$0.66 premium

UndervaluedFair: $140.22Overvalued

Intrinsic value data unavailable for PRE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PEP5 strengths · Avg: 9.0/10
Return on EquityProfitability
47.5%10/10

Every $100 of equity generates 47 in profit

EPS GrowthGrowth
137.0%10/10

Earnings expanding 137.0% YoY

Market CapQuality
$185.30B9/10

Large-cap with strong market position

P/E RatioValuation
17.7x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.50B8/10

Generating 1.5B in free cash flow

PRE3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
107.7%10/10

Revenue surging 107.7% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Areas to Watch

PEP3 concerns · Avg: 2.7/10
Price/BookValuation
8.9x4/10

Trading at 8.9x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Debt/EquityHealth
2.411/10

Elevated debt levels

PRE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$310.43M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-22.1%2/10

ROE of -22.1% — below average capital efficiency

Free Cash FlowQuality
$-12.33M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : PEP

The strongest argument for PEP centers on Return on Equity, EPS Growth, Market Cap. PEG of 1.46 suggests the stock is reasonably priced for its growth.

Bull Case : PRE

The strongest argument for PRE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 107.7% demonstrates continued momentum.

Bear Case : PEP

The primary concerns for PEP are Price/Book, Piotroski F-Score, Debt/Equity. Debt-to-equity of 2.41 is elevated, increasing financial risk.

Bear Case : PRE

The primary concerns for PRE are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

PEP profiles as a value stock while PRE is a hypergrowth play — different risk/reward profiles.

PEP carries more volatility with a beta of 0.37 — expect wider price swings.

PRE is growing revenue faster at 107.7% — sustainability is the question.

PEP generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

PEP scores higher overall (71/100 vs 32/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

PepsiCo Inc

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

PepsiCo, Inc. is an American based multinational food, snack, and beverage corporation headquartered in Harrison, New York, in the hamlet of Purchase. PepsiCo's business encompasses all aspects of the food and beverage market. It oversees the manufacturing, distribution, and marketing of its products.

Prenetics Global Ltd

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Prenetics Global Ltd (PRE) is an innovative health technology company that specializes in advanced genetic and diagnostic testing solutions, offering invaluable health insights to consumers and healthcare professionals alike. With a robust focus on research and development, Prenetics has built a strong international footprint through strategic partnerships and collaborations, enhancing its market visibility. As a frontrunner in personalized medicine, the company is strategically positioned to leverage the growing demand for accessible health data, presenting a compelling investment opportunity within the dynamic healthcare sector.

Want to dig deeper into these stocks?